RT Journal Article SR Electronic T1 Earlier cancer diagnosis in primary care: a feasibility economic analysis of ThinkCancer! JF BJGP Open JO BJGP Open FD Royal College of General Practitioners SP BJGPO.2022.0130 DO 10.3399/BJGPO.2022.0130 VO 7 IS 1 A1 Bethany Fern Anthony A1 Stefanie Disbeschl A1 Nia Goulden A1 Annie Hendry A1 Julia Hiscock A1 Zoe Hoare A1 Jessica Roberts A1 Jan Rose A1 Alun Surgey A1 Nefyn Howard Williams A1 Daniel Walker A1 Richard Neal A1 Clare Wilkinson A1 Rhiannon Tudor Edwards YR 2023 UL http://bjgpopen.org/content/7/1/BJGPO.2022.0130.abstract AB Background UK cancer survival rates are much lower compared with other high-income countries. In primary care, there are opportunities for GPs and other healthcare professionals to act more quickly in response to presented symptoms that might represent cancer. ThinkCancer! is a complex behaviour change intervention aimed at primary care practice teams to improve the timely diagnosis of cancer.Aim To explore the costs of delivering the ThinkCancer! intervention to expedite cancer diagnosis in primary care.Design & setting Feasibility economic analysis using a micro-costing approach, which was undertaken in 19 general practices in Wales, UK.Method From an NHS perspective, micro-costing methodology was used to determine whether it was feasible to gather sufficient economic data to cost the ThinkCancer! intervention. Owing to the COVID-19 pandemic, ThinkCancer! was mainly delivered remotely online in a digital format. Budget impact analysis (BIA) and sensitivity analysis were conducted to explore the costs of face-to-face delivery of the ThinkCancer! intervention as intended pre-COVID-19.Results The total costs of delivering the ThinkCancer! intervention across 19 general practices in Wales was £25 030, with an average cost per practice of £1317 (standard deviation [SD]: 578.2). Findings from the BIA indicated a total cost of £34 630 for face-to-face delivery.Conclusion Data collection methods were successful in gathering sufficient health economics data to cost the ThinkCancer! intervention. Results of this feasibility study will be used to inform a future definitive economic evaluation alongside a pragmatic randomised controlled trial (RCT).